In two PhIII wins for Allergan/Molecular Partners, wet AMD drug shows non-inferiority to Lucentis
It’s good news for Allergan and Molecular Partners’ wet AMD drug. The duo announced Thursday that abicipar has met its endpoints in two Phase III trials, proving non-inferiority to the market-leading Lucentis.
In both 8- and 12-week regimens, abicipar met its primary endpoints, but also showed the incidence of intraocular inflammation was higher in patients on abicipar than those on Lucentis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.